Pharmamel Drug Discovery Pharmamel Drug Discovery Pharmamel Drug Discovery Pharmamel Drug Discovery
  • Home
  • Company
    • About us
    • Founding partners
    • Board of directors
    • Contact
  • Research
    • Pathologies
    • Clinical trials
    • Documents and publications
    • Collaborations
  • Patents
    • Melatonin injectable for Sepsis
    • Melatonin injectable for viral diseases
    • Melatonin injectable for Cancer
    • Melatonin Gel for Mucositis
    • Licenses
  • Investors
    • Open capital round
    • Financial information
    • Other relevant information
    • Shareholder and investor information
    • Invest
  • News

  • English
  • Español

HomeNewsNews Pharmamel

Category: News Pharmamel

Pharmamel will go public to finance a revolutionary drug.

8 de May de 2024

Pharmamel announces the capital increase campaign “Go to BME Scaleup”

24 de April de 2024

Pharmamel launches the capital increase campaign “Go to BME Scaleup”

17 de April de 2024

The BME Pre-Market Environment welcomes Pharmamel

19 de March de 2024

Pharmamel begins the path to going public, entering the BME pre-market environment.

19 de March de 2024

Capital Cell invests in Pharmamel for the development of new drugs based on melatonin

24 de January de 2024

Pharmamel revolutionizes sepsis treatment with a melatonin drug

21 de June de 2023

PROJECT ID: IDI-20200938


PROJECT TITLE: DEVELOPMENT OF TRIALS FOR THE PREVENTION OF MORTALITY ASSOCIATED WITH SARS-COV2 (COVID-19) INFECTION IN HOSPITALIZED PATIENTS
Summary: This involves the development of a project through which to demonstrate the efficacy of injectable Melatonin for the prevention of mortality associated with SARS-Cov2 (COVID-19) infection in hospitalized patients.
Grant amount: €606,511.31

Contact
  • +34 958 419 143
  • C/ Ganivet 6, oficina 20-21. 18009 Granada
  • info@pharmameldrugdiscovery.com
Information
  • Privacy policy
  • Cokies policy
  • Legal Notice

PHARMAMEL S.L. © 2025

Pharmamel Drug Discovery
  • Home
  • Company
    • About us
    • Founding partners
    • Board of directors
    • Contact
  • Research
    • Pathologies
    • Clinical trials
    • Documents and publications
    • Collaborations
  • Patents
    • Melatonin injectable for Sepsis
    • Melatonin injectable for viral diseases
    • Melatonin injectable for Cancer
    • Melatonin Gel for Mucositis
    • Licenses
  • Investors
    • Open capital round
    • Financial information
    • Other relevant information
    • Shareholder and investor information
    • Invest
  • News
Uso de Cookies

Utilizamos cookies propias y de terceros para analizar el uso del sitio web y mostrarte publicidad relacionada con tus preferencias sobre la base de un perfil elaborado a partir de tus hábitos de navegación (por ejemplo, páginas visitadas).

Técnicas Always active
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Estadísticas
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
Configurar
  • {title}
  • {title}
  • {title}